The current treatment of triple‐negative breast cancer (TNBC) is still primarily based on platinum‐based chemotherapy. However, TNBC cells frequently develop resistance to platinum and experience relapse after drug withdrawal. It is crucial to specifically target and eliminate cisplatin‐tolerant cells after platinum administration. Here, it is reported that upregulated N6 ‐methyladenosine (m 6 A) modification drives the development of resistance in TNBC cells during cisplatin treatment. Mechanistically, histone deacetylase 2 (HDAC2) mediates delactylation of methyltransferase‐like 3 (METTL3), facilitating METTL3 interaction with Wilms’‐tumor‐1‐associated protein and subsequently increasing m 6 A of transcript‐associated DNA damage repair. This ultimately promotes cell survival under cisplatin. Furthermore, pharmacological inhibition of HDAC2 using Tucidinostat can enhance the sensitivity of TNBC cells to cisplatin therapy. This study not only elucidates the biological function of lactylated METTL3 in tumor cells but also highlights its negative regulatory effect on cisplatin resistance. Additionally, it underscores the nonclassical functional mechanism of Tucidinostat as a HDAC inhibitor for improving the efficacy of cisplatin against TNBC.
Background: To assess the efficacy of Nimotuzumab in combination with first-line chemoradiotherapy treatment in Chinese patients with primary III-IVb stage nasopharyngeal carcinoma.Methods: Patients with primary locoregionally advanced nasopharyngeal carcinoma who were treated with intensity-modulated radiotherapy (IMRT) and concurrent cisplatin-based chemotherapy between January 2008 and December 2013 at a single institution were retrospectively reviewed. Group A received at least 6 doses of Nimotuzumab, while Group B did not receive Nimotuzumab. A propensity score matching method was used to match patients from each group in a 1:3 ratio.Results: In total, 730 eligible patients were propensity matched, with 184 patients in Group A and 546 patients in Group B. Significant differences were not observed in the patient and tumor characteristics between Group A and Group B. At a median follow-up of 74.78 months (range 3.53–117.83 months), locoregional recurrence, distant failure and death were observed in 10.68, 11.10 and 16.03% of all patients, respectively. The estimated 5-year locoregional relapse–free survival, distant metastasis–free survival, progression-free survival and overall survival in the Group A versus Group B were 85.34% versus 89.79% (P = 0.156), 93.09% versus 85.61% (P = 0.012), 79.96% versus 77.99% (P = 0.117) and 88.91% versus 78.30% (P = 0.006), respectively.Conclusions: This nimotuzumab-containing regimen resulted in improved long-term survival of III-IVb stage NPC patients and warrants further prospective evaluation.
Colorectal cancer (CRC) progression is driven by complex metabolic alterations, including aberrant N‐glycosylation patterns that critically influence tumor development. However, the metabolic and functional roles of N‐glycosylation in CRC remain poorly understood. Herein, comprehensive proteomic and N‐linked intact glycoproteomics analyses are performed on 45 CRC tumors, and normal adjacent tissues (NATs) are matched, identifying 7125 intact N‐glycopeptides from 704 glycoproteins. Through analysis of glycoform expression profiles and structural characteristics, a glycosylation site–protein function association network is constructed to uncover metabolic dysregulation driven by N‐glycosylation in CRC. Moreover, an arithmetic model is developed that integrates N‐glycan expression patterns, which effectively distinguishes tumors from NATs, reflecting metabolic reprogramming in cancer. These findings identify Chloride Channel Accessory 1 (CLCA1) and Olfactomedin 4 (OLFM4) as potential metabolic biomarkers for CRC diagnosis. Immunohistochemistry and Cox regression analyses validated the prognostic power of these markers. Notably, the critical role of specific N‐glycosylation at N196 of Adipocyte plasma membrane‐associated protein (APMAP) is highlighted, a key player in tumor metabolism and CRC progression, providing a potential target for therapeutic intervention. These findings offer valuable insights into the metabolic roles of N‐glycosylation in CRC, advancing biomarker discovery, enhancing metabolic‐based diagnostic precision, and improving personalized treatment strategies targeting cancer metabolism.
The application of microfluidic technology to manipulate cells or biological particles is becoming one of the rapidly growing areas, and various microarray trapping devices have recently been designed for high throughput single-cell analysis and manipulation. In this paper, we design a double-slit microfluidic chip for hydrodynamic cell trapping at the single-cell level, which maintains a high capture ability. The geometric effects on flow behaviour are investigated in detail for optimizing chip architecture, including the flow velocity, the fluid pressure, and the equivalent stress of cells. Based on the geometrical parameters optimized, the double-slit chip enhances the capture of HeLa cells and the drug experiment verifies the feasibility of the drug delivery.
Esophageal squamous cell carcinoma (ESCC) exhibits high prevalence in China and poor prognosis despite neoadjuvant chemotherapy (NACT), with significant chemoresistance development. Tumor-associated metabolic reprogramming and NACT-induced cellular stress promote lactate accumulation, which serves as a precursor for lysine lactylation (Kla), a post-translational modification (PTM) potentially regulating cancer progression. We hypothesized that systematic characterization of the lactylome in response to NACT could reveal critical molecular mechanisms underlying treatment and identify new therapeutic vulnerabilities in ESCC. Herein, through comprehensive proteomic and lactylome profiling of tumor and adjacent normal tissues from 31 ESCC patients (with or without NACT treatment), we identified 8281 proteins and 1836 Kla sites across 62 samples. NACT induced substantial lactylome alterations with 307 differentially expressed Kla sites predominantly in non-histone proteins involved in DNA damage response and metabolic pathways. Our data revealed that while NACT-induced suppression of energy metabolism, coupled with upregulated HRD1 complex expression, may exert potential pro-apoptotic effects, the activation of ribosome biogenesis and increased nucleoprotein lactylation triggered tumor-protective mechanisms. Mechanistically, we demonstrated that DNA damage and elevated lactate levels induced PARP1 K654 lactylation, enhancing its enzymatic activity and augmenting poly(ADP-ribosyl)ation of downstream targets, potentially playing a pivotal role in chemotherapy resistance-associated pathways. This comprehensive tissue-level landscape of Kla dynamics in ESCC response to chemotherapy establishes Kla as a critical regulatory mechanism in treatment response, potentially offering novel therapeutic targets and predictive biomarkers for personalized treatment strategies.
Microdroplet dosing to cell on a chip could meet the demand of narrow diffusion distance, controllable pulse dosing and less impact to cells. In this work, we studied the diffusion process of microdroplet cell pulse dosing in the three-layer sandwich structure of PDMS (polydimethylsiloxane)/PCTE (polycarbonate) microporous membrane/PDMS chip. The mathematical model is established to solve the diffusion process and the process of rhodamine transfer to micro-traps is simulated. The rhodamine mass fraction distribution, pressure field and velocity field around the microdroplet and cell surfaces are analyzed for further study of interdiffusion and convective diffusion effect. The cell pulse dosing time and drug delivery efficiency could be controlled by adjusting microdroplet and culture solution velocity without impairing cells at micro-traps. Furthermore, the accuracy and controllability of the cell dosing pulse time and maximum drug mass fraction on cell surfaces are achieved and the drug effect on cells could be analyzed more precisely especially for neuron cell dosing.